Publications by authors named "Ian Joseph Cohen"
Article Synopsis
- The study reports zero early relapses (before 30 months) in 24 patients with isolated limb Ewing sarcoma treated using an intensified protocol called SCMCIE94.
- The treatment included chemotherapy, radiation, and limb salvage surgery, showing promising long-term survival rates for patients with localized disease.
- The findings suggest that the success in preventing early relapse is likely due to the specific changes in the SCMCIE94 protocol, despite the small sample size, and highlight the need for further strategies for managing late relapses.
Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue.
Cancer Chemother Pharmacol
June 2017
Purpose: To challenge the view that the dose of folinic acid rescue after high-dose methotrexate (MTX) has no significance in the prevention of neurotoxicity and to present the minority view that neurotoxicity can be prevented by an adequate dose of folinic acid, without compromising treatment results. Several fallacies that led to the misunderstanding of post MTX neurotoxicity are presented.
Methods: Data mining using search engines was used to find relevant publications, and an e-mail survey of more than 60 authors of articles in this field was performed.
Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect?
Cancer Chemother Pharmacol
February 2017
How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity?
Pediatr Blood Cancer
January 2014
To determine the optimal time of folinic acid rescue after methotrexate (MTX) treatment in patients with ALL, we selected and evaluated relevant studies that included doses, rescue delay, and side effects. Rescue at 42-48 hours resulted in considerable toxicity, except when low doses of MTX were used (1 g/m(2)) or serum MTX levels remained consistently low at 24, 30, and 36 hours. Rescue started at 30-36 hours was safe.
View Article and Find Full Text PDFHigh-dose methotrexate is effective in osteosarcoma so what is the problem?
J Pediatr Hematol Oncol
December 2009